Literature DB >> 31502884

Management of induction failures in newly diagnosed transplant-eligible multiple myeloma.

Morie A Gertz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31502884      PMCID： PMC6944754          DOI： 10.1080/10428194.2019.1663424

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.

Authors:  Joanna Blocka; Thomas Hielscher; Carsten Mueller-Tidow; Hartmut Goldschmidt; Jens Hillengass
Journal:  Leuk Lymphoma       Date:  2019-08-19

2.  Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.

Authors:  Morie A Gertz; Shaji Kumar; Martha Q Lacy; Angela Dispenzieri; David Dingli; Suzanne R Hayman; Francis K Buadi; William J Hogan
Journal:  Blood       Date:  2010-01-20       Impact factor: 22.113

3.  Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.

Authors:  Yael C Cohen; Erel Joffe; Noam Benyamini; Meletios A Dimopoulos; Evangelos Terpos; Svetlana Trestman; Viki Held-Kuznetsov; Irit Avivi; Efstathios Kastritis
Journal:  Leuk Lymphoma       Date:  2016-01-04

4.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

5.  Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Authors:  Ravi Vij; Shaji Kumar; Mei-Jie Zhang; Xiaobo Zhong; Jiaxing Huang; Angela Dispenzieri; Muneer H Abidi; Jennifer M Bird; César O Freytes; Robert Peter Gale; Tamila L Kindwall-Keller; Robert A Kyle; Daniel J Landsburg; Hillard M Lazarus; Reinhold Munker; Vivek Roy; Manish Sharma; Dan T Vogl; Baldeep Wirk; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-01       Impact factor: 5.742

6.  Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.

Authors:  Sung-Eun Lee; Jae-Ho Yoon; Seung-Hwan Shin; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Seok Lee; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park; Chang-Ki Min
Journal:  Ann Hematol       Date:  2013-10-02       Impact factor: 3.673

7.  The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.

Authors:  Tsutomu Kobayashi; Junya Kuroda; Shin-ichi Fuchida; Satoshi Murakami; Mayumi Hatsuse; Akira Okano; Toshiki Iwai; Yasuhiko Tsutsumi; Yuri Kamitsuji; Teruaki Akaogi; Eri Kawata-Iida; Daisuke Shimizu; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Mitsushige Nakao; Ryoichi Takahashi; Hiroto Kaneko; Nobuhiko Uoshima; Yutaka Kobayashi; Chihiro Shimazaki; Masafumi Taniwaki
Journal:  Intern Med       Date:  2012-03-01       Impact factor: 1.271

8.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Graham H Jackson; Faith E Davies; Charlotte Pawlyn; David A Cairns; Alina Striha; Corinne Collett; Anna Hockaday; John R Jones; Bhuvan Kishore; Mamta Garg; Cathy D Williams; Kamaraj Karunanithi; Jindriska Lindsay; Matthew W Jenner; Gordon Cook; Nigel H Russell; Martin F Kaiser; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan
Journal:  Lancet Oncol       Date:  2018-12-14       Impact factor: 41.316

Review 9.  Association of response endpoints with survival outcomes in multiple myeloma.

Authors:  S Lonial; K C Anderson
Journal:  Leukemia       Date:  2013-07-19       Impact factor: 11.528
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.